Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay

The current number of drugs available for the treatment of Alzheimer’s disease (AD) is strongly limited and their benefit for therapy is given only in the early state of the disease. An effective therapy should affect those processes which mainly contribute to the neuronal decay. There hav...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Max Holzer, Nico Schade, Ansgar Opitz, Isabel Hilbrich, Jens Stieler, Tim Vogel, Valentina Neukel, Moritz Oberstadt, Frank Totzke, Christoph Schächtele, Wolfgang Sippl, Andreas Hilgeroth
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2018-09-01
Colecção:Molecules
Assuntos:
AD drug discovery
synthesis
derivatives
structure-activity
lead structure
Acesso em linha:http://www.mdpi.com/1420-3049/23/9/2335
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados